Loading...
Market
How many doses of mRESVIA RSV Vaccine will be administered in Canada by Nov 8, 2025?
2
Resolution / Starting Odds
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 1.5 million • 25%
More than 1.5 million • 25%
Reports from Health Canada or Moderna's official press releases
Story
Moderna's mRESVIA RSV Vaccine Approved by Health Canada for Adults 60 and Older
Nov 8, 2024, 03:13 PM
Moderna has received approval from Health Canada for its respiratory syncytial virus (RSV) vaccine, mRESVIA, for adults aged 60 years and older. This marks the first mRNA-based vaccine for RSV to be authorized in Canada. The approval was announced on Friday, making it a significant milestone for the vaccine maker. The stock ticker for Moderna is $MRNA.
View original story
Similar markets
Less than 1 million • 25%
1 million to 3 million • 25%
3 million to 5 million • 25%
More than 5 million • 25%
Less than 1 million • 25%
1-3 million • 25%
3-5 million • 25%
More than 5 million • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
More than 30 countries • 25%
Decrease by less than 10% • 25%
Decrease by 10% to 20% • 25%
Decrease by 20% to 30% • 25%
Decrease by more than 30% • 25%
Less than 1 million • 25%
1-5 million • 25%
5-10 million • 25%
More than 10 million • 25%
Less than 5 million • 25%
5 million to 10 million • 25%
10 million to 15 million • 25%
More than 15 million • 25%
Less than 10 million • 25%
10-20 million • 25%
21-30 million • 25%
More than 30 million • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%